Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04729153
  4. Details
NCT04729153 Clinical Trial

Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity

Covid19 Clinical Trial

Official title:
Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04729153
Other study ID # DAADs and covid-19
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 2021
Est. completion date March 2022

Study information
Verified date January 2021
Source Assiut University
Contact Eman Adel
Phone 01096883754
Email emanadel9594@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Evaluate effect of DAADs on covid-19 disease.

Description:

If Chronic HCV patients who already received DAADs are protected against covid 19 and considered to be immune or not And if DAADS can be used in ttt of covid 19

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 100
Est. completion date March 2022
Est. primary completion date February 2022
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. HCV patient with or without LC. 2. >18 years old. 3. Received DAADs at 2019. Exclusion Criteria: 1. Combined HCV and HIV infected patients. 2. Combined HCV and HBV infected patients. 3. < 18 years old. 4. Pregnant or breast-feeding patients. 5. Patients with autoimmune disease. 6. Patients with multiorgan failure, active cancer, renal insufficiency. 7. Patients received immunosuppressive drugs. 8. Immune compromised patients. 9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• DAAD Compound
Sofosbuvir , Daclatasvir and ribavirin

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluate the effect of DAADs on covid -19 If chronic HCV patients who received DAADs suspected to be infected by covid-19 by having findings suggest covid 19 infection in MSCT chest or clinically symptoms or confirmed by nasopharyngeal swab . And if infected what about severity , if they need hospital admission or oxygen therapy or mechanical ventilation ,if they still alive or died 12 months (from 1/2/2021 to 1/2/2022)
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3